Stevanato Group S.p.A (STVN) Total Non-Current Liabilities (2020 - 2026)
Stevanato Group S.p.A (STVN) posted quarterly Total Non-Current Liabilities of -$89.9 million for Q1 2026, down 3.36% year-over-year from -$93.0 million in Q1 2025, and down 2.44% quarter-over-quarter from -$87.8 million in Q4 2025.
Stevanato Group S.p.A (STVN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Stevanato Group S.p.A (STVN) has reported Total Non-Current Liabilities for 7 consecutive years, with -$89.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 3.36% year-over-year to -$89.9 million; the TTM figure through Mar 2026 stood at -$89.9 million (down 3.36% YoY), while the FY2025 annual figure was -$87.8 million, up 3.71% from the prior year.
- Total Non-Current Liabilities declined to -$89.9 million in Q1 2026 per STVN's latest filing, from -$87.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at -$39.3 million in Q2 2022 and bottomed at -$91.2 million in Q3 2025.
- Historically, Total Non-Current Liabilities has averaged -$73.3 million across 5 years, with a median of -$78.8 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 116.16% — and 2025, when it rose 3.71%.
- Stevanato Group S.p.A's Total Non-Current Liabilities stood at -$54.0 million in 2022, then tumbled by 38.55% to -$74.8 million in 2023, then slipped by 21.9% to -$91.2 million in 2024, then climbed by 3.71% to -$87.8 million in 2025, then declined by 2.44% to -$89.9 million in 2026.
- Business Quant data shows STVN's Total Non-Current Liabilities at -$89.9 million in Q1 2026, -$87.8 million in Q4 2025, and -$91.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 1.92 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 48.34 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 6.34 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 985.45 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 17.56 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 8.96 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 3.98 Bn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 12.41 Bn |
| 10 | Stevanato Group S.p.A | 6.18 Bn | 6.07 Bn | 100.91 Mn | -89.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -89.27 Mn |
| Mar 31, 2026 | -89.91 Mn |
| Dec 31, 2025 | -87.77 Mn |
| Sep 30, 2025 | -91.19 Mn |
| Jun 30, 2025 | -88.41 Mn |
| Mar 31, 2025 | -86.99 Mn |
| Dec 31, 2024 | -91.15 Mn |
| Sep 30, 2024 | -81.38 Mn |
| Jun 30, 2024 | -78.83 Mn |
| Mar 31, 2024 | -78.65 Mn |
| Dec 31, 2023 | -74.78 Mn |
| Sep 30, 2023 | -80.45 Mn |
| Jun 30, 2023 | -74.05 Mn |
| Mar 31, 2023 | -57.32 Mn |
| Dec 31, 2022 | -53.97 Mn |
| Sep 30, 2022 | -51.02 Mn |
| Jun 30, 2022 | -39.27 Mn |
| Mar 31, 2022 | -41.41 Mn |
| Dec 31, 2021 | -41.53 Mn |
| Sep 30, 2021 | 315.78 Mn |